Overview

Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma

Status:
Not yet recruiting
Trial end date:
2027-08-15
Target enrollment:
Participant gender:
Summary
The purpose of this research is to help researchers find out if SP-3164 is safe and if it may be of benefit in the treatment of patients with Non-Hodgkin's lymphoma that has progressed after prior treatment, or that never responded to previous treatment.
Phase:
Early Phase 1
Details
Lead Sponsor:
Salarius Pharmaceuticals, LLC